TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...

Safety concerns included a 58% rate of treatment-related adverse events, with severe cases like immune-related colitis and a ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...

Immunotherapy—could that be an option for me, doctor?” is a question frequently asked by patients with colorectal cancer. The ...

Jon Desjardins, far left, is happy to be around for his family, thanks to successful treatment with immunotherapy after surgery for colorectal cancer. He joined a clinical trial led by Dr. Yelena ...

Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...

Immunotherapy for stage 4 prostate cancer is revolutionizing the way advanced disease is being treated, offering hope for patients worldwide. Unlike conventional treatment methods such as surgery and ...

A research team led by the Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of ...